Jun 24 |
Scholar Rock provides preclinical data for its investigational obesity candidate
|
Jun 24 |
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
|
Jun 3 |
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
|
May 28 |
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
|
May 22 |
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
|
May 20 |
Scholar Rock to Participate in Upcoming Investor Conferences
|
May 14 |
Scholar Rock to Host Investor Day on May 22, 2024
|
May 7 |
Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis
|
May 7 |
Scholar Rock GAAP EPS of -$0.59
|
May 7 |
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
|